Medtronic today announced its intent to acquire Contego Medical.
A press release notes that the acquisition will build on Medtronic’s US distribution agreement with Contego, first announced in January 2025. The deal specifically expands the Medtronic portfolio of differentiated carotid technologies, broadening patient access to therapies for carotid artery and peripheral vascular disease.
“With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease,” said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health, which is part of the company’s cardiovascular portfolio. “By pairing Medtronic’s deep clinical expertise in peripheral and neurovascular technologies with Contego’s next-generation treatments backed by strong and consistent clinical data, we intend to become an undisputed leader in carotid revascularisation.”
“Contego was founded to address unmet needs in clinical practice by developing technologies designed to improve outcomes while simultaneously simplifying procedures. Deepening our partnership with Medtronic is an exciting next chapter,” said Ravish Sachar, founder and CEO of Contego Medical. “We’re proud of our team and grateful to the physicians, study sites, employees, and investors who helped bring these technologies to patients.”
The planned acquisition includes Contego’s recently US Food and Drug Administration (FDA)-approved Neuroguard integrated embolic protection (IEP) Direct system, which is noted to be the first and only transcarotid artery revascularisation (TCAR) system with IEP (TCAR-IEP) in addition to flow reversal.
Beyond carotid revascularisation, the acquisition includes Contego’s Excipio thrombectomy devices, which complement Medtronic’s Liberant thrombectomy system in the treatment of peripheral vascular disease.
Medtronic expects to complete the transaction, valued at $380 million, in the third quarter of its fiscal year.











